Elevance Health said on December 10, 2025 its Board of Directors elected Amy W. Schulman to serve as an independent director, effective January 12, 2026, with a term expiring at the Company's 2028 annual meeting of shareholders.

1. 01

   Elevance Health said on December 10, 2025 its Board of Directors elected Amy W. Schulman to serve as an independent director, effective January 12, 2026, with a term expiring at the Company's 2028 annual meeting of shareholders.

2. 02

   The company said the Board appointed Schulman to its Audit and Finance Committees. The Board determined that she qualifies as an independent director under NYSE listing standards and as an audit committee financial expert under SEC regulations.

3. 03

   Elevance Health said Schulman will receive compensation for her services as a director in accordance with the Company's standard compensation program for non-employee directors, and that there is no arrangement or understanding between Ms. Schulman and any other person pursuant to which she was elected to the Board.

4. 04

   The company said in its press release that Schulman is Managing Partner at Polaris Partners, a venture capital firm managing more than $4 billion across healthcare and technology investments, Chair of the Board of Alnylam Pharmaceuticals, Inc., and a former Executive Vice President and General Counsel of Pfizer.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.